• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Nevro Corp.

    12/4/24 4:27:18 PM ET
    $NVRO
    Medical/Dental Instruments
    Health Care
    Get the next $NVRO alert in real time by email
    SC 13G 1 e664057_sc13g-nevro.htm

     

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

    SCHEDULE 13G

    (Rule 13d-102)

     

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

    TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED

    PURSUANT TO RULE 13d-2(b)

     

    (Amendment No. ) *

     

    Nevro Corp. 

    (Name of Issuer)

     

    Common Stock, par value $0.001 per share

    (Title of Class of Securities)

     

    64157F103

    (CUSIP Number)

     

    November 19, 2024

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ☐  Rule 13d-1(b)

     

    ☒  Rule 13d-1(c)

     

    ☐  Rule 13d-1(d)

     

    (Page 1 of 8 Pages)

    _____________________________________________

    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    CUSIP No. 64157F103 13G Page 2 of 8 Pages

     

    1.

    NAME OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Shay Capital LLC

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

     

     

    (a) ☐

    (b) ☒

    3.

    SEC USE ONLY

     

     

    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

     

     

     NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    5.

    SOLE VOTING POWER

     

    1,969,797

     
    6.

    SHARED VOTING POWER

     

    0

     

    7.

     

    SOLE DISPOSITIVE POWER

     

    1,969,797

     

    8.

     

    SHARED DISPOSITIVE POWER

     

    0

     

    9.

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    1,969,797 (1)

    10.

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

     

     

    ☐

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    5.26%

    12.

    TYPE OF REPORTING PERSON*

     

    CO

      

                               

    (1) Includes 641,100 shares of common stock issuable upon exercise of call options that are currently exercisable.

     

    CUSIP No. 64157F103 13G Page 3 of 8 Pages

     

    1.

    NAME OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Shay Capital Holdings LLC

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

     

     

    (a) ☐

    (b) ☒

    3.

    SEC USE ONLY

     

     

    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

     

     

     NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    5.

    SOLE VOTING POWER

     

    1,969,797

     
    6.

    SHARED VOTING POWER

     

    0

     

    7.

     

    SOLE DISPOSITIVE POWER

     

    1,969,797

     

    8.

     

    SHARED DISPOSITIVE POWER

     

    0

     

    9.

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    1,969,797 (1)(2)

    10.

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

     

     

    ☐

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    5.26%

    12.

    TYPE OF REPORTING PERSON*

     

    IA

     

                               

    (1) Includes 641,100 shares of common stock issuable upon exercise of call options that are currently exercisable.

    (2) Consists of securities directly beneficially owned by Shay Capital LLC, of which Shay Capital Holdings LLC is the sole manager.

     

    CUSIP No. 64157F103 13G Page 4 of 8 Pages

     

    Item 1(a). Name of Issuer:
       
     

    Nevro Corp.

       
    Item 1(b). Address of Issuer's Principal Executive Offices:
       
     

    1800 Bridge Parkway

    Redwood City, CA 94065

       
    Item 2(a). Name of Person Filing:
       
     

    Shay Capital LLC

    Shay Capital Holdings LLC

       
    Item 2(b). Address of Principal Business Office, or if None, Residence:
       
     

    The principal business address of each Reporting Person is 280 Park Avenue, 5th Floor West, New York, NY 10017.

       
    Item 2(c). Citizenship:
       
     

    Shay Capital LLC and Shay Capital Holdings LLC – Delaware

       
    Item 2(d). Title of Class of Securities:
       
     

    Common Stock, par value $0.001 per share

       
    Item 2(e). CUSIP Number:
       
     

    64157F103

         
    Item 3.

    If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:

       
    (a) ☐

    Broker or dealer registered under Section 15 of the Exchange Act.

         
    (b) ☐ Bank as defined in Section 3(a)(6) of the Exchange Act.
         
    (c) ☐

    Insurance company as defined in Section 3(a)(19) of the Exchange Act.

         
    (d) ☐

    Investment company registered under Section 8 of the Investment Company Act.

         
    (e) ☐ An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);

     

    CUSIP No. 64157F103 13G Page 5 of 8 Pages

     

    (f) ☐

    An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);

         
    (g) ☐

    A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);

         

    (h)

    ☐

    A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act;

         
    (i) ☐

    A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act;

         
    (j) ☐ A non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J);
         
    (k) ☐ Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

     

    If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please specify the type of institution: __________________________________________

     

    Item 4. Ownership.
         

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

         
    (a) Amount beneficially owned**:
         
     

     

    Shay Capital LLC – 1,969,797

    Shay Capital Holdings LLC – 1,969,797

         
    (b) Percent of class**:
         
     

     

    Shay Capital LLC – 5.26%

    Shay Capital Holdings LLC – 5.26% 

         
    (c) Number of shares as to which such person has**:
         
      (i) Sole power to vote or to direct the vote:
         
       

     

    Shay Capital LLC – 1,969,797

    Shay Capital Holdings LLC – 1,969,797

         
      (ii) Shared power to vote or to direct the vote:
         
       

     

    Shay Capital LLC – 0

    Shay Capital Holdings LLC – 0

     

      (iii)

    Sole power to dispose or to direct the disposition of:

         
       

     

    Shay Capital LLC – 1,969,797

    Shay Capital Holdings LLC – 1,969,797

     

    CUSIP No. 64157F103 13G Page 6 of 8 Pages

     

      (iv)

    Shared power to dispose or to direct the disposition of:

         
       

     

    Shay Capital LLC – 0

    Shay Capital Holdings LLC – 0

      

    **See footnotes on cover pages which are incorporated by reference herein.

     

    Item 5. Ownership of Five Percent or Less of a Class.
       

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities check the following ☐

       
       
       
    Item 6. Ownership of More Than Five Percent on Behalf of Another Person.
       
      N/A
       
    Item 7.

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

       

    If a parent holding company or Control person has filed this schedule, pursuant to Rule 13d-1(b)(1)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company or control person has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.

       
      N/A
       
    Item 8. Identification and Classification of Members of the Group.
       

    If a group has filed this schedule pursuant to ss.240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to ss.240.13d-1(c) or ss.240.13d-1(d), attach an exhibit stating the identity of each member of the group.

       
      See Exhibit B
       
    Item 9. Notice of Dissolution of Group.
       

    Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity. See Item 5.

       
      N/A

     

    CUSIP No. 64157F103 13G Page 7 of 8 Pages

     

    Item 10. Certifications.
       

    "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11."

     

    CUSIP No. 64157F103 13G Page 8 of 8 Pages

     

    SIGNATURE

      

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

     

    SHAY CAPITAL LLC

    By: Shay Capital Holdings LLC, its Manager

      

    By: /s/ Elan Foxman

    Name: Elan Foxman

    Title: Chief Financial Officer

     

     

    SHAY CAPITAL HOLDINGS LLC

      

    By: /s/ Elan Foxman

    Name: Elan Foxman

    Title: Chief Financial Officer

     

     

    Dated: December 4, 2024

     

     

    Exhibit List

     

    Exhibit A. Joint Filing Agreement.

     

    Exhibit B. Item 8 Statement.

     

     

      

    Exhibit A

     

    Joint Filing Agreement

     

    The undersigned agree that this Schedule 13G, and all amendments thereto, relating to the common stock of Nevro Corp. shall be filed on behalf of the undersigned.

     

    SHAY CAPITAL LLC

    By: Shay Capital Holdings LLC, its Manager

      

    By: /s/ Elan Foxman

    Name: Elan Foxman

    Title: Chief Financial Officer

     

     

    SHAY CAPITAL HOLDINGS LLC

      

    By: /s/ Elan Foxman

    Name: Elan Foxman

    Title: Chief Financial Officer

     

     

    Dated: December 4, 2024

     

     

    Exhibit B

     

    Due to the relationships between them, the reporting persons hereunder may be deemed to constitute a “group” with one another for purposes of Section 13(d)(3) of the Securities Exchange Act of 1934.

     

     

     

    Get the next $NVRO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $NVRO

    DatePrice TargetRatingAnalyst
    2/10/2025$4.50 → $5.85Underperform → Hold
    Jefferies
    2/7/2025$6.00 → $5.85Neutral → Overweight
    Piper Sandler
    12/3/2024$5.00Equal Weight
    Wells Fargo
    12/2/2024$9.00 → $4.00Equal-Weight → Underweight
    Morgan Stanley
    8/9/2024Sell → Neutral
    Citigroup
    8/8/2024Underperform → Peer Perform
    Wolfe Research
    8/7/2024Mkt Outperform → Mkt Perform
    JMP Securities
    8/7/2024Neutral → Underweight
    JP Morgan
    More analyst ratings

    $NVRO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Mccormick Shawn returned 46,035 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - NEVRO CORP (0001444380) (Issuer)

      4/3/25 4:30:33 PM ET
      $NVRO
      Medical/Dental Instruments
      Health Care
    • Director Kosaraju Sridhar returned 46,575 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - NEVRO CORP (0001444380) (Issuer)

      4/3/25 4:30:35 PM ET
      $NVRO
      Medical/Dental Instruments
      Health Care
    • Director Grossman D Keith returned 228,552 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - NEVRO CORP (0001444380) (Issuer)

      4/3/25 4:30:38 PM ET
      $NVRO
      Medical/Dental Instruments
      Health Care

    $NVRO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Nevro Reports Fourth-Quarter and Full-Year 2024 Financial Results

      REDWOOD CITY, Calif., March 4, 2025 /PRNewswire/ -- Nevro Corp. (NYSE:NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today reported its fourth-quarter and full-year 2024 financial results. "We are pleased that adjusted EBITDA for the full-year 2024 came in ahead of our revised expectations and that our balance sheet remains strong, reflecting our ongoing focus on working capital management and the benefits from our 2024 restructurings," said Kevin Thornal, Nevro's president and CEO. "Importantly, we look forward to joining forces with Globus Medical to achieve our full potential and working together to free

      3/4/25 4:15:00 PM ET
      $GMED
      $NVRO
      Medical/Dental Instruments
      Health Care
    • Globus Medical to Acquire Nevro Corp. to Expand Treatment Options for Patients

      AUDUBON, Pa. and REDWOOD CITY, Calif., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Globus Medical (NYSE:GMED), a leading musculoskeletal solutions company, and Nevro Corp. (NYSE:NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced they have entered into a definitive agreement for Globus Medical to acquire all shares of Nevro in an all-cash transaction. Under the terms of the agreement, which was unanimously approved by the boards of directors of both companies, Globus Medical will acquire all shares of Nevro for $5.85 per share. The transaction represents a total equity value of approximately $250 million.

      2/6/25 9:30:21 AM ET
      $GMED
      $NVRO
      Medical/Dental Instruments
      Health Care
    • Nevro Announces New Employee Inducement Grants Under NYSE Rule 303A.08

      REDWOOD CITY, Calif., Jan. 21, 2025 /PRNewswire/ -- Nevro Corp. (NYSE:NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, announced that on January 7, 2025, the Compensation Committee of the Company's Board of Directors granted inducement restricted stock unit awards covering 21,026 shares of Nevro's common stock to 10 new non-executive employees to induce them to accept employment with Nevro. Each award was granted under the Nevro Corp. 2023 Inducement Award Plan and vests over a three-year period, subject to continued employment with Nevro through each vesting date. Each award was granted as a material induceme

      1/21/25 4:30:00 PM ET
      $NVRO
      Medical/Dental Instruments
      Health Care

    $NVRO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Nevro Corp.

      SC 13G - NEVRO CORP (0001444380) (Subject)

      12/4/24 4:27:18 PM ET
      $NVRO
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Nevro Corp.

      SC 13D/A - NEVRO CORP (0001444380) (Subject)

      11/14/24 5:31:36 PM ET
      $NVRO
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Nevro Corp.

      SC 13G/A - NEVRO CORP (0001444380) (Subject)

      11/14/24 5:18:25 PM ET
      $NVRO
      Medical/Dental Instruments
      Health Care

    $NVRO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Nevro upgraded by Jefferies with a new price target

      Jefferies upgraded Nevro from Underperform to Hold and set a new price target of $5.85 from $4.50 previously

      2/10/25 7:02:54 AM ET
      $NVRO
      Medical/Dental Instruments
      Health Care
    • Nevro upgraded by Piper Sandler with a new price target

      Piper Sandler upgraded Nevro from Neutral to Overweight and set a new price target of $5.85 from $6.00 previously

      2/7/25 8:27:53 AM ET
      $NVRO
      Medical/Dental Instruments
      Health Care
    • Wells Fargo initiated coverage on Nevro with a new price target

      Wells Fargo initiated coverage of Nevro with a rating of Equal Weight and set a new price target of $5.00

      12/3/24 7:38:11 AM ET
      $NVRO
      Medical/Dental Instruments
      Health Care

    $NVRO
    Financials

    Live finance-specific insights

    See more
    • Nevro Reports Fourth-Quarter and Full-Year 2024 Financial Results

      REDWOOD CITY, Calif., March 4, 2025 /PRNewswire/ -- Nevro Corp. (NYSE:NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today reported its fourth-quarter and full-year 2024 financial results. "We are pleased that adjusted EBITDA for the full-year 2024 came in ahead of our revised expectations and that our balance sheet remains strong, reflecting our ongoing focus on working capital management and the benefits from our 2024 restructurings," said Kevin Thornal, Nevro's president and CEO. "Importantly, we look forward to joining forces with Globus Medical to achieve our full potential and working together to free

      3/4/25 4:15:00 PM ET
      $GMED
      $NVRO
      Medical/Dental Instruments
      Health Care
    • Globus Medical to Acquire Nevro Corp. to Expand Treatment Options for Patients

      AUDUBON, Pa. and REDWOOD CITY, Calif., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Globus Medical (NYSE:GMED), a leading musculoskeletal solutions company, and Nevro Corp. (NYSE:NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced they have entered into a definitive agreement for Globus Medical to acquire all shares of Nevro in an all-cash transaction. Under the terms of the agreement, which was unanimously approved by the boards of directors of both companies, Globus Medical will acquire all shares of Nevro for $5.85 per share. The transaction represents a total equity value of approximately $250 million.

      2/6/25 9:30:21 AM ET
      $GMED
      $NVRO
      Medical/Dental Instruments
      Health Care
    • Nevro Reports Third-Quarter 2024 Financial Results

      Reaffirms Full-Year 2024 Revenue Guidance and Raises Full-Year 2024 Adjusted EBITDA Guidance REDWOOD CITY, Calif., Nov. 11, 2024 /PRNewswire/ -- Nevro Corp. (NYSE:NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today reported its third-quarter 2024 financial results, reaffirmed its full-year 2024 revenue guidance and raised its full-year 2024 adjusted EBITDA guidance. "Our worldwide revenue and adjusted EBITDA came in better than we anticipated in the third quarter of 2024. In addition, our cash position reflects the benefits from our restructurings earlier this year as well as our focus on working capital ma

      11/11/24 4:05:00 PM ET
      $NVRO
      Medical/Dental Instruments
      Health Care

    $NVRO
    SEC Filings

    See more
    • SEC Form 15-12G filed by Nevro Corp.

      15-12G - NEVRO CORP (0001444380) (Filer)

      4/14/25 8:30:09 AM ET
      $NVRO
      Medical/Dental Instruments
      Health Care
    • SEC Form EFFECT filed by Nevro Corp.

      EFFECT - NEVRO CORP (0001444380) (Filer)

      4/8/25 12:15:06 AM ET
      $NVRO
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SCHEDULE 13D/A filed by Nevro Corp.

      SCHEDULE 13D/A - NEVRO CORP (0001444380) (Subject)

      4/4/25 3:49:25 PM ET
      $NVRO
      Medical/Dental Instruments
      Health Care

    $NVRO
    Leadership Updates

    Live Leadership Updates

    See more
    • Nevro Enters Into Cooperation Agreement With Engaged Capital

      Appoints Kirt P. Karros to Board of Directors REDWOOD CITY, Calif., Feb. 21, 2024 /PRNewswire/ -- Nevro Corp. (NYSE:NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that it has entered into a Cooperation Agreement with Engaged Capital, LLC ("Engaged Capital"), pursuant to which Kirt P. Karros has been appointed to Nevro's Board of Directors ("the Board") as well as the Audit Committee of the Board effective February 20, 2024. Mr. Karros is an accomplished finance executive with extensive experience in finance, including capital allocation and financial planning and analysis, as well as strategi

      2/21/24 4:06:00 PM ET
      $NVRO
      Medical/Dental Instruments
      Health Care
    • Nevro Appoints Jon R. Shear as Vice President, Corporate Development

      REDWOOD CITY, Calif., April 19, 2021 /PRNewswire/ -- Nevro Corp. (NYSE:NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced the appointment of Jon Shear to the newly created position of Vice President, Corporate Development, effective immediately.   "Jon is uniquely qualified for this new role and brings extensive insight and understanding of the medical technologies industry to Nevro," said D. Keith Grossman, Chairman, CEO and President of Nevro. "As a member of our leadership team, he will be responsible for leading Nevro's strategic planning process, overseeing the business development function and

      4/19/21 7:00:00 AM ET
      $NVRO
      Medical/Dental Instruments
      Health Care
    • Nevro Appoints Julie D. Dewey as Vice President, Investor Relations and Corporate Communications

      REDWOOD CITY, Calif., Nov. 30, 2020 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced that Julie Dewey has joined the company as vice president, investor relations and corporate communications, effective immediately.   "Julie has a tremendous depth of experience in all areas of investor relations and corporate communications, a deep knowledge of capital markets and has earned an outstanding reputation within the investment community," said Rod MacLeod, CFO of Nevro. "As a member of our leadership team, she will be instrumental in communicating the Nevro story a

      11/30/20 7:00:00 AM ET
      $NVRO
      Medical/Dental Instruments
      Health Care